Thu, Oct 30, 2014, 9:18 AM EDT - U.S. Markets open in 12 mins.

Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

clemcaldwell 1472 posts  |  Last Activity: Oct 13, 2014 3:20 PM Member since: Jul 7, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    13G

    by clemcaldwell Oct 12, 2014 4:15 PM
    clemcaldwell clemcaldwell Oct 13, 2014 3:20 PM Flag

    You are correct Fidelity sold some. But in the scheme of everything they do it's nothing unusual.

  • Reply to

    13G

    by clemcaldwell Oct 12, 2014 4:15 PM
    clemcaldwell clemcaldwell Oct 13, 2014 3:16 PM Flag

    The message was sent to me by Susan Hubbard from Exelixis IR

  • Reply to

    13G

    by clemcaldwell Oct 12, 2014 4:15 PM
    clemcaldwell clemcaldwell Oct 13, 2014 3:15 PM Flag

    I was surprised to receive this message from Susan Hubbard.

    I have noted that you a regular poster on the Yahoo message board, so
    always available to help clear up any factual misperceptions or
    misunderstandings of aspects of EXEL's business.

    Regards,
    Susan Hubbard

  • clemcaldwell by clemcaldwell Oct 12, 2014 4:15 PM Flag

    As reflected in Fidelity's 13F on file with the SEC as of June 30, 2014, Fidelity's position in EXEL was 29,027,479.
    Per the 13G filing as of September 30, 2014, Fidelity position in EXEL was 17,135,441
    or 8.782% of EXEL's shares outstanding.

    Hope that helps.
    Susan Hubbard

  • Reply to

    Check out who just filed a 13g on Exel

    by neers87 Oct 10, 2014 10:59 AM
    clemcaldwell clemcaldwell Oct 12, 2014 4:10 PM Flag

    Well that didn't answer my question.Did they just purchase 17 million shares? All the rest you stated I already knew.They may have sold 17 million+ shares this past week.

  • Reply to

    Cabo plus trastuzumab in BCa

    by wilderguide Oct 10, 2014 5:57 PM
    clemcaldwell clemcaldwell Oct 11, 2014 4:24 PM Flag

    Wild you may like this site? Cancer network Home of the journal Oncology.There is an article called Dual Inhibition of VEGF and c-MET in Cancer Promises to Decrease Metastasis.
    February 29, 2012 | Pancreatic Cancer, Neuroendocrine Tumors
    By Anna Azvolinsky, PhD
    It quotes Dana T. Aftab, PhD, part of the translational research team at Exelixis, and coauthor of the Cancer Discovery paper.

  • Reply to

    Check out who just filed a 13g on Exel

    by neers87 Oct 10, 2014 10:59 AM
    clemcaldwell clemcaldwell Oct 11, 2014 3:13 PM Flag

    Did they purchase over 17 million shares?

  • Reply to

    Cabo plus trastuzumab in BCa

    by wilderguide Oct 10, 2014 5:57 PM
    clemcaldwell clemcaldwell Oct 10, 2014 6:07 PM Flag

    Nice but.That is years away.
    Estimated Enrollment: 40
    Study Start Date: October 2014
    Estimated Study Completion Date: February 2022
    Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)

  • clemcaldwell clemcaldwell Oct 8, 2014 3:14 PM Flag

    I wasn't asking for judgement.I did wonder if their estimates were correct.I'm certainly not the first to copy and paste articles from the Headlines section.

  • clemcaldwell clemcaldwell Oct 7, 2014 3:57 PM Flag

    Gee you get nothing but thumbs down all the time?

  • EXEL's third quarter financial results and conference call are on Tuesday,
    November 4 after market close.

  • clemcaldwell clemcaldwell Oct 7, 2014 3:19 PM Flag

    I don't understand how they can say an upward trend over the past 60 days.Then say as estimates have risen from -$1.53/share two months ago to just -$1.43/share right now?

  • clemcaldwell clemcaldwell Oct 7, 2014 3:07 PM Flag

    Exelixis, has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. And for technical investors there is some hope when looking at EXEL given that, according to its RSI reading of 18.35, it is now in oversold territory.
    Other Factors Yet, EXEL’s low RSI value isn’t the only reason to have some optimism over a coming turnaround, as there has been plenty of positive earnings estimate revision activity as of late. This is especially true when investors take a deep dive into some of these estimate revision stats and recent changes to Exelixis’s earnings consensus.Over the past two months, investors have seen 4 earnings estimate revisions move higher, compared with none lower, at least when looking at the key current year time frame. And the consensus estimate for EXEL has also been on an upward trend over the past 60 days, as estimates have risen from -$1.53/share two months ago to just -$1.43/share right now.

  • clemcaldwell clemcaldwell Oct 7, 2014 3:01 PM Flag

    Instead, genomics is expected to allow doctors to interrogate the tumor at genetic levels that previously were unavailable.
    Instead, genomics is expected to allow doctors to interrogate the tumor at genetic levels that previously were unavailable.What we're talking about here is not in any way new," Dr. Bryce said. We're taking that same concept and perhaps do it in great depth.
    We've moved past that low hanging fruit, and we're really trying to go for that really hard to reach fruit at this point.
    Dr. Bryce equates such an advancement with the fable of Goldilocks, where a young girl is particularly picky about the temperature of her porridge until she finds one that's just right. Point being, modern medicine soon may enter an era where treatments are no longer one-size-fits-all because of genomics.
    That's especially significant because advancements in medical treatments of cancer over the past 50 years have been unable to improve the survival rate, Dr. Bryce said. It's hovered about 4 percent to 7 percent. He's hopeful that increased use of genomics in the medical field will enrich that survival rate.
    The goal of therapy is to reduce the burden of disease and reduce symptoms, and also to extend life — but of course we're not satisfied with that answer,Dr. Bryce said. We're always pushing, we're always looking for improved therapies.

  • clemcaldwell clemcaldwell Oct 7, 2014 2:53 PM Flag

    We're going to be doing more genetic testing, more genomic testing and creating more genomic profiles,Dr. Ferber said during his introductory presentation at the four-day conference. The lynchpin here is translating that genetic result into an actionable event that will benefit the patient.
    We've got a tool box here, and there's a number of tools within that box, but the lynchpin at the end of this is you need to have access to better drugs to tailor the treatment of that tumor.
    Mayo Clinic Dr. Tim Curry readily admits the hardest part for him was learning the complicated terminology of genomics, which he characterized as a word salad.
    Dr. Alan Bryce, an oncology specialist at the Mayo Clinic, said the ideas might seem revolutionary, but they're really an extension of medical practices that were first introduced more than a century ago. As one example, he said doctors removed a woman's ovaries in the 1800s as a way to reduce estrogen and combat breast cancer.

  • clemcaldwell clemcaldwell Oct 6, 2014 5:14 PM Flag

    It refuses to post the rest. For some reason?

  • It took medical experts 13 years and $3 billion to complete the Human Genome Project in 2003, but Mayo Clinic experts say medical advancements have nearly made a $1,000 personal genome a reality.
    Dr. Matthew Ferber of the Mayo Clinic said the plummeting price — it still cost about $100 million to map a personal genome in 2008 — has created opportunities for individualized medicine. That could prove especially important in developing targeted treatments for cancerous tumors once considered death sentences.
    The trick now is translating that promise into medical practice.The creation of direct-to-consumer markets is the subject of a Mayo Clinic conference called Center for Individualized Medicine: Introduction to Genomic Medicine for Practitioners, which started Sunday at the Mayo Civic Center. Multiple sessions on genetics are scheduled through Wednesday night. Dozens from around the globe are attending to be brought up to speed on the emerging science.

  • Mayo Clinic has announced a pilot program to bring health providers into the work environment using telemedicine kiosks.

    "Mayo Clinic Health Connection" will start with Mayo Clinic Health System employees in Austin and Albert Lea.

    The system will use a product called HealthSpot, "which combines robust cloud-based software and a private walk-in kiosk that offer solutions to care for patients in their place of work."

    Doctors, nurse practitioners and physician assistants from both Mayo Clinic and Mayo Clinic Health System will meet with patients who can visit the kiosk with no appointment required.

    Dr. Matt Bernard, Southeast Minnesota region Primary Care Service Line chairman, said that Mayo "is committed to reducing health-care expenses for employees and employers by improving access to medical services through convenient and more-affordable care."

    Mayo Clinic has announced a pilot program to bring health providers into the work environment using telemedicine kiosks.
    "Mayo Clinic Health Connection" will start with Mayo Clinic Health System employees in Austin and Albert Lea.
    The system will use a product called HealthSpot, "which combines robust cloud-based software and a private walk-in kiosk that offer solutions to care for patients in their place of work."
    Doctors, nurse practitioners and physician assistants from both Mayo Clinic and Mayo Clinic Health System will meet with patients who can visit the kiosk with no appointment required.
    Dr. Matt Bernard, Southeast Minnesota region Primary Care Service Line chairman, said that Mayo "is committed to reducing health-care expenses for employees and employers by improving access to medical services through convenient and more-affordable care."The move follows successful rollouts by Mayo Clinic and Olmsted Medical Center of community-based convenience clinics.
    Mayo Clinic's Express Care Clinics at Hy-Vee stores provide access to health providers who review minor ailments such as sore throats, sinus infections and

  • Reply to

    Anyone know about COMET-2?

    by laoxao855 Oct 3, 2014 9:08 PM
    clemcaldwell clemcaldwell Oct 4, 2014 2:21 PM Flag

    FDA approved in May 2003 for NSCLC, Gefitinib is currently marketed in over 64 countries.In June 2005 the FDA withdrew approval for use in new patients due to lack of evidence that it extended life.
    In Europe gefitinib is indicated since 2009 in advanced NSCLC in all lines of treatment for patients harbouring EGFR mutations. This label was granted after gefitinib demonstrated as a first line treatment to significantly improve progression-free survival vs. a platinum doublet regime in patients harbouring such mutations. IPASS has been the first of four phase III trials to have confirmed gefitinib superiority in this patient population.[citation needed]
    In most of the other countries where gefitinib is currently marketed it is approved for patients with advanced NSCLC who had received at least one previous chemotherapy regime. However, applications to expand its label as a first line treatment in patients harbouring EGFR mutations is currently in process based on the latest scientific evidence.[citation needed] As at August 2012 New Zealand has approved gefitinib as first line treatment for patients with EGFR mutation for naive locally advanced or metastatic, unresectable NSCLC. This publicly funded for an initial 4 month term and renewal if no progression.
    While gefitinib has yet to be proven to be effective in other cancers, there is potential for its use in the treatment of other cancers where EGFR overexpression is involved.[citation needed]
    (Erlotinib is another EGFR tyrosine kinase inhibitor that has a similar mechanism of action to gefitinib.)

  • Reply to

    Seeking Alpha article by Christopher F. Davis

    by clemcaldwell Oct 2, 2014 5:28 PM
    clemcaldwell clemcaldwell Oct 3, 2014 5:19 PM Flag

    And what company are you analyzing for? Where are you published genius? Are you paid a fair amount for your expert advice by a major Financial Corporation?

EXEL
1.70-0.05(-2.94%)Oct 29 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.